BioSpace News Archive

Business

Forma Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 5, 2022

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease (SCD), prostate cancer and other rare hematologic diseases and cancers, today announced that it will release second quarter 2022 financial results Friday, August 5, 2022.

July 29, 2022
·
1 min read
Drug Development

Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell Carcinoma

Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell Carcinoma.

July 29, 2022
·
44 min read
Drug Development

Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19

Enanta Pharmaceuticals, Inc . today announced positive topline data from a Phase 1 study assessing the safety, tolerability, and pharmacokinetics (PK) of orally administered single ascending doses (SAD) and multiple ascending doses (MAD) of EDP-235 in healthy adult subjects.

July 29, 2022
·
7 min read
Business

Concert Pharmaceuticals to Report Second Quarter 2022 Results on August 4, 2022

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the second quarter of 2022, on Thursday, August 4, 2022, before the U.S. financial markets open.

July 29, 2022
·
1 min read
Lone Star Bio

Apollo Endosurgery Announces Publication in the Lancet of Landmark Study for the Endoscopic Sleeve Gastroplasty Procedure

Apollo Endosurgery, Inc. announced today the electronic publication of the landmark Multi-center ESG Randomized Interventional Trial (MERIT) Study in The Lancet .

July 29, 2022
·
7 min read